IL6 and congenital rubella syndrome: Therefore, patients with a high risk of severe CRS/ICANS, including those with a TB higher than 5%, might benefit from early interventions [20, 21] or the use of prophylactic drugs [22, 23], as well as from more stable and durable levels of IL-6 antagonist drugs such as siltuximab.